Which comorbidity classification best fits elderly candidates for radical prostatectomy? - Abstract

Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany.

 

Comorbidity assessment may assist in the treatment choice for elderly men with prostate cancer. There is, however, no consensus on the best comorbidity classification for this purpose. In this study, we used a heuristic approach to identify an optimal comorbidity classification in elderly men selected for radical prostatectomy.

A total of 1,106 men aged 65 years or older who underwent radical prostatectomy for clinically localized prostate cancer were stratified by 11 3-sided comorbidity classifications. Overall survival was the study endpoint. The comorbidity classifications were evaluated considering 4 statistical (height of hazard ratios and P values, survival difference between high and low risk patients, dose-response relationship) and 4 clinical demands (survival rates in low and high risk group, balance of the proportion of the risk groups). The 3 best classifications in each category received 3, 2, or 1 point. After adding all points, the classification with the highest score was considered best.

With one exception, all comorbidity classifications were significant predictors of overall survival. Comparing the highest with the lowest risk group, the hazard ratios ranged between 1.67 and 3.93. Concerning the fulfillment of clinical and statistical demands, the American Society of Anesthesiologists (ASA) physical status classification and 1 derivative of it that included further more clearly defined diseases were the most promising candidates.

Stratifying candidates for radical prostatectomy according to their mortality risk using the ASA classification as a backbone supplemented by a list of more clearly defined concomitant diseases could be useful in clinical practice and outcome studies.

Written by:
Froehner M, Hentschel C, Koch R, Litz RJ, Hakenberg OW, Wirth MP.   Are you the author?

Reference: Urol Oncol. 2011 Apr 15. Epub ahead of print.
doi: 10.1016/j.urolonc.2011.03.002

PubMed Abstract
PMID: 21498089

UroToday.com Prostate Cancer Section

 

 

email news signup